Table 1.
Baseline characteristics.
| Age (yr ± SD) | 33.7 (9.6) |
|---|---|
| Male-[no. (%)] | 29 (24.2) |
| Female-[no. (%)] | 91 (75.8) |
| Previous use DMT-[no. (%)] | 83 (69.2) |
| Interferon-beta | 51 (42.5) |
| Glatiramer acetate | 21 (17.5) |
| Fingolimod | 4 (3.3) |
| Other approved medications | 7 (5.8) |
| none-[no. (%)] | 37 (30.8) |
| Duration since MS diagnosis (mean yr ± SD) | 5.6 (5.8) |
| Mean score on EDSS | 3.8 (1.8) |
Baseline characteristics of evaluated patients. Other approved medications include, Triamcinolon (1), Azathioprin (1), Mitoxantron (4), Laquinimod (1). DMT, disease modifying therapy; yr, years; SD, standard deviation; no, number.